Items where authors include "Srivastava, T."

Article

Shah, B., Challagulla, S., Xu, S. et al. (7 more authors) (2025) Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma. Leukemia & Lymphoma, 66 (12). pp. 2238-2248. ISSN 1042-8194

Harnan, S. orcid.org/0000-0002-9318-9206, Kearns, B. orcid.org/0000-0001-7730-668X, Scope, A. orcid.org/0000-0003-1604-1758 et al. (11 more authors) (2024) Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model. Health Technology Assessment, 28 (73). ISSN 1366-5278

Woods, B. orcid.org/0000-0002-7669-9415, Schmitt, L. orcid.org/0000-0003-1052-488X, Jankovic, D. orcid.org/0000-0002-9311-1409 et al. (10 more authors) (2024) Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model. Health Technology Assessment, 28 (28). pp. 1-238. ISSN 1366-5278

Heathcote, L. orcid.org/0000-0001-8063-7447, Srivastava, T., Sarmah, A. et al. (3 more authors) (2023) A systematic review and statistical analysis of factors influencing the cost-effectiveness of transcatheter aortic valve implantation for symptomatic severe aortic stenosis. ClinicoEconomics and Outcomes Research, 15. pp. 459-475. ISSN 1178-6981

Thokala, P. orcid.org/0000-0003-4122-2366, Srivastava, T., Smith, R. et al. (5 more authors) (2023) Living health technology assessment: issues, challenges and opportunities. PharmacoEconomics, 41 (3). pp. 227-237. ISSN 1170-7690

Srivastava, T. orcid.org/0000-0002-5961-9348, Latimer, N.R. orcid.org/0000-0001-5304-5585 and Tappenden, P. orcid.org/0000-0001-6612-2332 (2021) Estimation of transition probabilities for state-transition models : a review of NICE appraisals. PharmacoEconomics, 39 (8). pp. 869-878. ISSN 1170-7690

Rubin, G., Walter, F.M., Emery, J. et al. (10 more authors) (2021) Electronic clinical decision support tool for assessing stomach symptoms in primary care (ECASS): a feasibility study. BMJ Open, 11 (3). e041795. ISSN 2044-6055

Saiyed, M., Byrnes, J., Srivastava, T. orcid.org/0000-0002-5961-9348 et al. (2 more authors) (2020) Cost-effectiveness of lenvatinib compared with sorafenib for the first-line treatment of advanced hepatocellular carcinoma in Australia. Clinical Drug Investigation, 40 (12). pp. 1167-1176. ISSN 1173-2563

Srivastava, T., Prabhu, V.S., Li, H. et al. (7 more authors) (2020) Cost-effectiveness of pembrolizumab as second-line therapy for the treatment of locally advanced or metastatic urothelial carcinoma in Sweden. European Urology Oncology, 3 (5). pp. 663-670. ISSN 2588-9311

Srivastava, T. orcid.org/0000-0002-5961-9348, Strong, M. orcid.org/0000-0003-1486-8233, Stevenson, M.D. orcid.org/0000-0002-3099-9877 et al. (1 more author) (2020) Improving cycle corrections in discrete time Markov models : a Gaussian quadrature approach. medRxiv. (Submitted)

Monograph

Srivastava, T. orcid.org/0000-0002-5961-9348, Chambers, D., Thomas, C. et al. (1 more author) (2019) ECASS health economic feasibility study. Report. ScHARR HEDS Discussion Papers . School of Health and Related Research, University of Sheffield , Sheffield.

Proceedings Paper

Srivastava, T., Strong, M., Stevenson, M.D. orcid.org/0000-0002-3099-9877 et al. (1 more author) (2019) PNS337: Improving on cycle corrections for time-homogeneous markov models. In: Value in Health. ISPOR Europe 2019, 02-07 Nov 2019, Copenhagen, Denmark. Elsevier , S821-S821.